Company Collaborating with Researchers at the University of Nottingham on Optimization and Evaluation of Novel Small Molecule GPR65 Inhibitors in Preclinical Brain…
Latest news
ThirtyFiveBio Awarded Innovate UK Biomedical Catalyst Grant to Advance GPR35 Inhibitor Program for Treatment of Gastrointestinal Disease and Cancers
Prestigious Award Provides Non-Dilutive Funding to Support Preclinical Activities Designed to Enable Translational Studies and Advancement into Clinical Development of First-in-Class GPR35…
Grey Wolf Therapeutics Reports Promising Preclinical Data from Research Collaboration with Immunocore in Oral Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023
New Data Demonstrate Ability of ERAP1 Inhibition to Generate and Upregulate Cancer Antigens to be Targeted by MHC Class I Directed T…
ThirtyFiveBio data debut: AACR 2023 poster presentation
ThirtyFiveBio were delighted to make our data debut at the American Association for Cancer Research (AACR) 2023 conference. CEO, James Westcott, presented…
Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours
First-in-Class ERAP1 Inhibitor Enters Clinical Development Study to Evaluate GRWD5769 as Monotherapy, as well as in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) …
ThirtyFiveBio Stealth Emergence
ThirtyFiveBio emerges from stealth with presentation of first data from GPR35 Antagonist Program at AACR 2023. Third Company Created by M:M Bio and…
Grey Wolf Therapeutics Closes Oversubscribed $49 Million Series B Financing to Advance First-of-its-Kind Neoantigen Creation Approaches
Premier Syndicate of Life Science Industry Investors led by Pfizer Ventures and Earlybird Venture Capital and including Canaan, Andera Partners, Oxford Science…
Grey Wolf Therapeutics Announces Clinical Supply Agreement with Regeneron for Trial Evaluating GRWD5769 in Combination with Libtayo® (cemiplimab)
Combination of First-in-Class ERAP1 Inhibitor and Anti-PD-1 Monoclonal Antibody to be Studied in Patients with a Range of Advanced Solid Tumours …
GWT to present preclinical data on first-in-class ERAP1 Inhibitors at SITC
Grey Wolf Therapeutics, a biotechnology company spearheading a new therapeutic approach to immuno-oncology driven by targeted neoantigen generation, today announced the presentation of promising preclinical in vivo data on the company’s first-in-class inhibitors of ERAP1 at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
Grey Wolf Therapeutics completes £10 million ($14 million) series A financing
Grey Wolf Therapeutics completes £10 million ($14 million) series A financing with Andera Partners and Canaan to fund development of immuno-oncology therapies…